The US firm’s oral plasma kallikrein inhibitor was associated with liver elevations in a number of Phase II patients, prompting a trial termination and shift in focus to an on-demand program. 

START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.